{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","groups":[{"description":"Participants With a Germline Mutation in Deoxyribonucleic Acid (DNA) Repair Genes","id":"OG000","title":"Comparison Group 1:Participants With a Germline Mutation in Deoxyribonucleic Acid (DNA) Repair Genes"},{"description":"Comparison Group 2 Participants With BRCA1 Associated Protein-1 (BAP1) Somatic Mutations","id":"OG001","title":"Comparison Group 2: Participants With BRCA1 Associated Protein-1 (BAP1) Somatic Mutations"},{"description":"Participants With no tumor tissue available for somatic mutation","id":"OG002","title":"Comparison Group 3: Participants With Neither Germline Mutations Nor BAP 1 Somatic Mutations"},{"description":"Participants With no tumor tissue available for somatic mutation","id":"OG003","title":"Participants Not Classified Under Comparison Groups"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Data is grouped as specified per protocol.","reportingStatus":"POSTED","timeFrame":"Adverse events were recorded from the study start date until prior to the study completion date, approximately 27 months and 11 days.","title":"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)","type":"PRIMARY","unitOfMeasure":"Participants"}